Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 569-571

  Volk, J ^a   Reinke, F ^a   Van Kuilenburg, A B P ^b   Van Gennip, A H ^b   Schlichting, C ^c   Ganser, A ^a   Schoffski P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c I Chirurgische Klinik   (Germany)

Author keywords

5 Fluorouracil metabolism; Chemotherapy; Dihydropyrimidine dehydrogenase deficiency; Irinotecan; Oxaliplatin; Raltitrexed

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; RALTITREXED;

ABDOMINAL CRAMP; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BONE MARROW DEPRESSION; CANCER RECURRENCE; CASE REPORT; COLON CANCER; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DYSESTHESIA; DYSPHAGIA; ENZYME DEFICIENCY; GENETIC DISORDER; HUMAN; LEUKOPENIA; LIVER METASTASIS; MALE; METABOLIC DISORDER; NAUSEA; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; STANDARD; STOMATITIS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OXIDOREDUCTASES; QUINAZOLINES; THIOPHENES;

EID: 0035016457     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011178111295     Document Type: Article

References (17)

1. Heggie GD, Sommadossi JP, Cross DS et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987; 47: 2203-6.
2. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68: 499-501.
3. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-tluorouracil chemotherapy. J Cancer Res 1993; 53: 5433-8.
4. Van Kuilenburg ABP, Vreken P, Beex LVAM et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997; 33: 2258-64.
5. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998; 12 (Suppl 7): 23-7.
6. Rothenberg ML. Efficiacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998; 25: 39-46.
7. Raymond L, Chaney SG, Taama A, Cvitkovic E. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71.
8. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77 (Suppl 2): 15-21.
9. Van Kuilenburg ABP, Van Lenthe H, Tromp A et al. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9-17.
10. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenuse activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4: 325-9.
11. Fleming RA, Milano GA, Gaspard MH et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993; 29A: 740-4.
12. Fernandez-Salguero PM, Sapone A, Wei X et al. Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics 1997; 7: 161-3.
13. Van Kuilenburg ABP, Vreken P, Abeling NGGM et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9.
14. Wiseman LR, Markham A, Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606-23.
15. Ito T, van Kuilenburg ABP, Bootsma AH et al. Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips. Clin Chem 2000; 46: 445-52.
16. Fleming RA, Milano G, Thyss A et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899-902.
17. Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: An overview. World J Surg 1997; 21: 748-62.